Literature DB >> 26221405

Successful diagnosis of hyperpyrexia induced by isoniazid in a child with suspected extra-pulmonary tuberculosis.

Caihong Qu1, Xiaoyan Li1, Zhenda Zheng2, Jieming Zhu2.   

Abstract

A 9-year-old boy received a rifampicin-isoniazid-ethambutol regimen for suspected extra-pulmonary tuberculosis, and glucurolactone and vitamin B6 to provide liver protection and decrease neurotoxicity associated with isoniazid. Baseline serum aminotransferase and total bilirubin levels were within normal limits before anti-tubercular treatment. After 4 days of treatment, the patient's body temperature increased (from 38.0°C to 40.1°C) and on the 11th day of treatment, serum chemistry results showed 400 U/L aspartate transaminase, 535 U/L alanine aminotransferase and 76.8 μmol/L total bile acid, which likely indicated drug-induced hepatic injury. After discontinuing isoniazid or administering anti-tubercular therapy without isoniazid, hyperpyrexia gradually resolved; hyperpyrexia reappeared following rechallenge with isoniazid. The patient's liver function returned to normal after symptomatic treatment. Thus, hyperpyrexia that accompanied hepatic injury was considered to be related to isoniazid. This case indicated that hyperpyrexia could also appear during anti-tubercular treatment owing to its hepatotoxicity.

Entities:  

Keywords:  Adverse drug reaction; hepatotoxicity; hyperpyrexia; isoniazid; suspected extra-pulmonary tuberculosis

Year:  2015        PMID: 26221405      PMCID: PMC4509350     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

1.  [Fulminant liver failure caused by antitubercular drugs. Report of a clinical case].

Authors:  L Girotto; A Gjonovich; G Preciso
Journal:  Minerva Anestesiol       Date:  2000-04       Impact factor: 3.051

2.  Adverse events with isoniazid preventive therapy: experience from a large trial.

Authors:  Alison D Grant; Kathryn T Mngadi; Clare L van Halsema; Mariëtha M Luttig; Katherine L Fielding; Gavin J Churchyard
Journal:  AIDS       Date:  2010-11       Impact factor: 4.177

3.  Toxic hepatitis with isoniazid and rifampin. A meta-analysis.

Authors:  M A Steele; R F Burk; R M DesPrez
Journal:  Chest       Date:  1991-02       Impact factor: 9.410

Review 4.  Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.

Authors:  F Durand; G Jebrak; D Pessayre; M Fournier; J Bernuau
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

Review 5.  Adverse reactions to first-line antituberculosis drugs.

Authors:  Eric J Forget; Dick Menzies
Journal:  Expert Opin Drug Saf       Date:  2006-03       Impact factor: 4.250

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Rifampicin exacerbates isoniazid-induced toxicity in human but not in rat hepatocytes in tissue-like cultures.

Authors:  C Shen; Q Meng; G Zhang; W Hu
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

8.  Use of isoniazid for latent tuberculosis infection in a public health clinic.

Authors:  Philip A LoBue; Kathleen S Moser
Journal:  Am J Respir Crit Care Med       Date:  2003-05-13       Impact factor: 21.405

9.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

10.  Adverse reactions due to directly observed treatment strategy therapy in Chinese tuberculosis patients: a prospective study.

Authors:  Xiaozhen Lv; Shaowen Tang; Yinyin Xia; Xiaomeng Wang; Yanli Yuan; Daiyu Hu; Feiying Liu; Shanshan Wu; Yuan Zhang; Zhirong Yang; Dehua Tu; Yixin Chen; Peiyuan Deng; Yu Ma; Ru Chen; Siyan Zhan
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

  10 in total
  1 in total

Review 1.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.